Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 20;9(8):388.
doi: 10.3390/biom9080388.

A Stage-Based Approach to Therapy in Parkinson's Disease

Affiliations
Review

A Stage-Based Approach to Therapy in Parkinson's Disease

Claudia Carrarini et al. Biomolecules. .

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder that features progressive, disabling motor symptoms, such as bradykinesia, rigidity, and resting tremor. Nevertheless, some non-motor symptoms, including depression, REM sleep behavior disorder, and olfactive impairment, are even earlier features of PD. At later stages, apathy, impulse control disorder, neuropsychiatric disturbances, and cognitive impairment can present, and they often become a heavy burden for both patients and caregivers. Indeed, PD increasingly compromises activities of daily life, even though a high variability in clinical presentation can be observed among people affected. Nowadays, symptomatic drugs and non-pharmaceutical treatments represent the best therapeutic options to improve quality of life in PD patients. The aim of the present review is to provide a practical, stage-based guide to pharmacological management of both motor and non-motor symptoms of PD. Furthermore, warning about drug side effects, contraindications, as well as dosage and methods of administration, are highlighted here, to help the physician in yielding the best therapeutic strategies for each symptom and condition in patients with PD.

Keywords: Parkinson’s disease; acetylcholinesterase inhibitors; amantadine; anticholinergics; dopamine-agonists; l-dopa; monoamine oxidase inhibitors; motor symptoms; non-motor symptoms; non-pharmacological therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Jankovic J. Parkinson’s disease: Clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry. 2008;79:368–376. doi: 10.1136/jnnp.2007.131045. - DOI - PubMed
    1. Connolly B.S., Lang A.E. Pharmacological treatment of Parkinson disease: A review. JAMA. 2014;311:1670–1683. doi: 10.1001/jama.2014.3654. - DOI - PubMed
    1. Postuma R.B., Berg D., Stern M., Poewe W., Olanow C.W., Oertel W., Obeso J., Marek K., Litvan I., Lang A.E., et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord. 2015;30:1591–1601. doi: 10.1002/mds.26424. - DOI - PubMed
    1. Gjerstad M.D., Wentzel-Larsen T., Aarsland D., Larsen J.P. Insomnia in Parkinson’s disease: Frequency and progression over time. J. Neurol. Neurosurg. Psychiatry. 2007;78:476–479. doi: 10.1136/jnnp.2006.100370. - DOI - PMC - PubMed
    1. Walsh K., Bennett G. Parkinson’s disease and anxiety. Postgrad. Med. J. 2001;77:89–93. doi: 10.1136/pmj.77.904.89. - DOI - PMC - PubMed

MeSH terms

Substances